Body mass index and the risk of male cancer mortality of various sites: 17-year follow-up of the Basel cohort study by Eichholzer, M et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2005
Body mass index and the risk of male cancer mortality of various
sites: 17-year follow-up of the Basel cohort study
Eichholzer, M; Bernasconi, F; Jordan, P; Stähelin, H B
Eichholzer, M; Bernasconi, F; Jordan, P; Stähelin, H B (2005). Body mass index and the risk of male cancer
mortality of various sites: 17-year follow-up of the Basel cohort study. Swiss Medical Weekly, 135(1-2):27-33.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Swiss Medical Weekly 2005, 135(1-2):27-33.
Eichholzer, M; Bernasconi, F; Jordan, P; Stähelin, H B (2005). Body mass index and the risk of male cancer
mortality of various sites: 17-year follow-up of the Basel cohort study. Swiss Medical Weekly, 135(1-2):27-33.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Swiss Medical Weekly 2005, 135(1-2):27-33.
Body mass index and the risk of male cancer mortality of various
sites: 17-year follow-up of the Basel cohort study
Abstract
QUESTIONS UNDER STUDY: There is growing evidence for a link between body weight and cancer
risk, but there is not a clear consensus yet. METHODS: We studied the association between body mass
index (BMI) and overall, lung, prostate and colon cancer mortality. In 1971/73, weight and height were
measured in 2974 men working in Basel, Switzerland. In 1990, the vital status of all participants was
assessed. RESULTS: 290 men had died from cancer, 87 from lung, 30 from prostate, and 22 from colon
cancer. In the predefined Cox Proportional Hazards Regression Models for survival analysis, a baseline
hazard was modified multiplicatively by covariates, i.e. the untransformed continuous variable "BMI"
was chosen as covariate. In addition it was assumed that the baseline hazard may be different for
smokers, non-smokers and different age groups (age at entry into study). Thus, multiple strata, i.e.
combinations of smoking status and age groups were allowed. With increasing BMI overall cancer
mortality did not change. Accordingly, the relative risk (RR) per 1-unit increase of BMI (unit = 1
kg/m2) was 1.03 (95% CI: 0.99-1.07). In relation to lung cancer, mortality did neither increase nor
decrease with increasing BMI (RR = 1.0; 95% CI 0.93- 1.07). The results for prostate cancer mortality
were similar, i.e. no correlation with BMI was observed (RR = 0.95; 95% CI: 0.93-1.18). The same was
true for colon cancer mortality (RR = 1.09; 95% CI: 0.92-1.24). CONCLUSIONS: This investigation
provides little evidence of an association between BMI and mortality of all cancers combined, cancer of
the lung, the prostate and the colon.
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Questions under study: There is growing evi-
dence for a link between body weight and cancer
risk, but there is not a clear consensus yet. 
Methods: We studied the association between
body mass index (BMI) and overall, lung, prostate
and colon cancer mortality. In 1971/73, weight and
height were measured in 2974 men working in
Basel, Switzerland. In 1990, the vital status of all
participants was assessed. 
Results: 290 men had died from cancer, 87 from
lung, 30 from prostate, and 22 from colon cancer.
In the predefined Cox Proportional Hazards Re-
gression Models for survival analysis, a baseline
hazard was modified multiplicatively by covariates,
i.e. the untransformed continuous variable “BMI”
was chosen as covariate. In addition it was assumed
that the baseline hazard may be different for smok-
ers, non-smokers and different age groups (age at
entry into study). Thus, multiple strata, i.e. com-
binations of smoking status and age groups were
allowed. With increasing BMI overall cancer mor-
tality did not change. Accordingly, the relative risk
(RR) per 1-unit increase of BMI (unit = 1 kg/m2)
was 1.03 (95% CI: 0.99–1.07). In relation to lung
cancer, mortality did neither increase nor decrease
with increasing BMI (RR = 1.0; 95% CI 0.93–
1.07). The results for prostate cancer mortality
were similar, i.e. no correlation with BMI was ob-
served (RR = 0.95; 95% CI: 0.93–1.18). The same
was true for colon cancer mortality (RR = 1.09;
95% CI: 0.92–1.24). 
Conclusions: This investigation provides little
evidence of an association between BMI and mor-
tality of all cancers combined, cancer of the lung,
the prostate and the colon.
Key words: BMI; cancer mortality; cohort study;
overall cancer; lung cancer; prostate cancer; colon cancer
Body mass index (BMI), defined as a person’s
weight in kilograms divided by the square of height
in meters, is often used in epidemiologic studies as
a proxy measure of overweight and obesity. It is
widely accepted that a high BMI is associated with
an increased risk to health, in particular with
regard to hypertension, diabetes mellitus, and
ischemic heart disease [1]. There is also growing
evidence for a link between body weight and can-
cer risk [2–5]. Calle and co-workers for example
showed a positive linear trend in death rates for all
cancers with increasing BMI [5]. Among western
men the three most common cancers in order of
incidence are lung, prostate, and colon/rectum [2].
These cancers are all considered to be related to
body weight, but there is not a clear consensus yet
[4]. Obese men have been reported to be at higher
risk of colorectal cancer in most but not all studies
[3, 4]. Previous surveys on the relationship be-
tween incident prostate cancer and BMI have been
controversial, predominantly no association, or a
small increased risk among heavy men was found.
The few mortality data, on the other hand, showed
an increased risk more consistently [6]. Finally, an
elevated risk of lung cancer associated with lower
levels of BMI has been reported in a number of
studies [7]. 
Evidence on body weight and cancer is not
straightforward because the cancer process itself
may cause loss of weight, even before the cancer is
evident [2, 8–10]. Manson et al. 1987 [11] pro-
posed several approaches to minimize this effect,
i.e. careful screening of the patient population at
baseline, exclusion of subjects experiencing sub-
stantial weight loss in the previous year, and to dis-
regard mortality within the first few years of fol-
low-up. On the other hand, analytic and simula-
tion work by Allison et al. suggested that exclud-
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ing subjects who died during the first few years of
follow-up did not substantially decrease confound-
ing by occult disease and under certain circum-
stances, did increase such bias [12, 13]. Moreover,
smoking has to be considered as a potential con-
founding factor, because smokers on the one hand
are at higher risk for cancer and, on the other hand
are, on average, thinner than non-smokers.
The present report deals with cancer-related
deaths (n = 290) during the 17-year follow-up
(1971/73–1990) of 2974 men of the Basel Study.
The hypothesis of an association between body
mass index at baseline and cancer mortality risk
was tested for all cancers combined and for cancer
of the lung, prostate, and colon. No attempt was
made to exclude mortality during the first few
years of follow-up.
Materials and methods
Study population
In 1971–1973, 2974 men were recruited for a cohort
study in Basel, Switzerland. These were healthy volunteers
of relatively high and homogenous socioeconomic status,
most of them working in the former three major chemi-
cal/pharmaceutical companies in Basel. The age range of
study participants was from 20 to 79 years. At recruitment
all participants had a clinical examination (including
height and weight measurements), underwent laboratory
investigations, and completed a questionnaire. Body
height and weight were measured in light indoor clothing
without shoes. 
The analysis was stratified according to the potential
confounders “age” and “smoking” (see below). It is well
known that age is a major risk factor for all cancer sites
considered and that BMI increases with age in the general
population. As shown in table 2 of the present study, can-
cer cases of all considered sites were on average older than
survivors. Furthermore, BMI increased with advancing
age (data not shown). Smoking is a known major risk fac-
tor for lung cancer. For prostate and colorectal cancer ev-
idence is not conclusive, but results of recent studies are
promising. Furthermore, smokers were on average thin-
ner than non-smokers (mean BMI 25.1 and 25.8 respec-
tively). At baseline no information was collected on past
smoking, duration, age at which smoking started, and
depth of inhalation. Moreover, no further information on
socioeconomic status and recent weight loss was assessed
and no screening for cancer was done. 
In 1990 the vital status was assessed for the entire co-
hort of the 2974 men. Information about death was pro-
vided by employers, relatives, and local authorities. Death
certificates were used to identify causes of deaths. A total
of 801 men died during the 17 years of follow-up, includ-
ing 290 from cancer (International classification of Dis-
eases, Injuries, and Causes of Death, eight Revision (ICD-
8), codes 140-239). For the present analyses, the malig-
nancies were grouped into all cancer (n = 290), lung can-
cer (n = 87, ICD-8 code 162), prostate cancer (n = 30, ICD-
8 code 185), and colon cancer (n = 22, ICD-8 code 153). 
Statistical analysis
Descriptive analysis
Group means and standard deviations of BMI, age, as
well as number and percentages of smokers at baseline are
provided for cancer deaths, all deaths and survivors. 
In order to display the relationship of BMI graphi-
cally for each endpoint survival curves, where the BMI was
categorized into quartiles (figures 1–4), were plotted for
smokers and non-smokers. Concrete values for BMI-
quartiles were:
min 25% 50% 75% max
16.37 23.51 25.31 27.44 42.92
Risk analysis
Inferential analysis of the explanatory variables was
based on Cox Proportional Hazards Regression Model for
survival analysis [14, 15]. The time for each endpoint was
coded as “time in study“ (in days) for the cases. The 30th
of June 1990 was set as the final date for the study. Sur-
vivors up to this date and subjects dying from another
cause than the specific endpoint (all cancers, lung cancer,
colon cancer, prostate cancer) were considered as right-
censored (with respect to the corresponding endpoint). 
In Cox models, a baseline hazard is modified multi-
plicatively by covariates. In our case, the untransformed
continuous variable “BMI” was chosen as covariate in
order to look for association between survival and baseline
BMI. It was assumed that the baseline hazard may be dif-
ferent for smokers and non-smokers as well as for differ-
ent age groups (age at entry into study). So, we allowed for
multiple strata, i.e. combinations of smoking status (smok-
ers, non-smokers) and age group. The age groups were
chosen as ≤50 y, >50 y–65 y and >65 y for the endpoint ‘all
cancers’ and ≤60 y as well as >60 y for the other endpoints
due to the limited number of cases. Tables 1a and 1b show
the number of cases for each stratum and endpoint. 
The linearity of BMI was checked by plotting the
martingale residuals from a model with BMI removed ver-
sus BMI. For all endpoints, the relation looked linear. The
correlation coefficient between transformed survival time
and the scaled Schoenfeld residuals was tested in order to
check the proportional hazard assumption [16]. In this
analysis we did not check for competing risks, i.e. the pos-
sibility that censoring did not occur completely at random
but by other deaths with possible dependencies to the end-
points under consideration. All statistical analyses were
performed using S-Plus version 6.1 for Windows [17].
Strata number of all cancers
Nonsmoker and age <50 years 25
Nonsmoker and age >50–65 years 77
Nonsmoker and age >65 years 30
Smoker and age <50 years 17
Smoker and age >50–65 years 99
Smoker and age >65 years 42
Total 290
Table 1a.
Number of all cancer
cases in each stratum
of age, smokers and
non-smokers of male
participants of the
Basel Cohort Study.
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Descriptive analysis
Baseline characteristics of male cancer deaths
(n = 290), all deaths (n = 801) and survivors (n =
2,173) are given in table 2. Group means for BMI
were slightly higher in the overall cancer group
and in the groups of prostate and colon cancer
deaths than in the survivors group. Mean BMI of
lung cancer cases and survivors on the other hand
did not differ. On average, cancer cases of all the
considered sites were about 10 years older than
survivors. As expected, a higher percentage of
smokers was observed in the lung (75%) and all
cancer (55%) groups than among survivors (40%).
Slightly higher percentages were also seen in the
prostate cancer and the all deaths groups, but not
in the colon cancer group. 
In order to display the relationship of BMI
graphically for each endpoint, survivor curves,
where the BMI was categorized into quartiles,
were plotted for smokers and non-smokers (figures
1–4). 
Risk analysis
In table 3 the results of the analyses based on
the Cox Proportional Hazards Regression Models
are summarized.
With increasing BMI overall cancer mortality
did not change. Accordingly, the relative risk (RR)
Strata Number of lung Number of prostate Number of colon 
cancer deaths cancer deaths cancer deaths
Nonsmoker 8 5 9
and age <60 years
Nonsmoker 14 11 5
and age >60 years
Smoker 27 4 3
and age <60 years
Smoker 38 10 5
and age >60 years
Total 87 30 22
Table 1b.
Number of cases in
each stratum of age,
smokers and non-
smokers by cancer
site of male partici-
pants of the Basel
Cohort Study.
Results
Mean Survivors All cancers Lung cancer Prostate cancer Colon cancer All deaths
(standard deviation) (n = 2173) (n = 290) (n = 87) (n = 30) (n = 22) (n = 801)
BMI 25.3 (3.0) 26.1 (3.5) 25.6 (3.5) 26.3 (3.9) 26.5 (2.4) 26.0 (3.4)
Age 1971–73 (years) 49 (9.2) 59.7 (7.8) 61 (6.4) 63.8 (6.9) 60.6 (8.1) 59.7 (8.4)
Number of smokers (%) 872 (40.1) 158 (54.5) 65 (74.7) 14 (46.7) 8 (36.4) 410 (51.2)
BMI, body mass index, which is calculated as weight in kilograms divided by the square of height in meters.
Table 2.
Baseline characteris-
tics of survivors,
cases of deaths from
cancer of various
sites and other
deaths of male par-
ticipants of the Basel
Cohort Study.
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Figure 1.
Survival curves for
all cancers by smok-
ing status and BMI
quartiles: follow-up
of male participants
of the Basel study
1971/73–1990.
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Figure 2.
Survival curves for
lung cancer by smok-
ing status and BMI
quartiles: follow-up
of male participants
of the Basel study
1971/73–1990.
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Figure 3.
Survival curves for
prostate cancer by
smoking status and
BMI quartiles: follow-
up of male partici-
pants of the Basel
study 1971/73–1990.
Figure 4.
Survival curves for
colon cancer by
smoking status and
BMI quartiles: follow-
up of male partici-
pants of the Basel
study 1971/73–1990.
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In this 17-year follow-up of 2974 men, we in-
vestigated the associations between body mass
index and cancer mortality risk. We found no as-
sociations between BMI and mortality risk for
overall, lung, prostate and colon cancer mortality.
As in our study, Seidell et al. in their large
Dutch cohort observed no clear association be-
tween total cancer mortality and BMI. The lowest
mortality was seen in slightly overweight men. In
non-smokers no associaton was found at all [18].
In the Health Professional Follow-up study nei-
ther the 65+ year olds nor the younger study par-
ticipants showed any significant relation between
BMI and mortality due to overall cancer [19]. In
the American Cancer Society’s prospective study,
conducted in 1960–1972, the mortality ratio in
males was highest (1.33) among men who were
40% or more overweight and in those who were
20% or more underweight. In male nonsmokers,
mortality ratio did not change much with increas-
ing weight index [20]. A U-shaped association be-
tween BMI and cancer occurrence as well as can-
cer mortality was also seen in a Japanese cohort
study [21]. Low BMI affected cancer occurrence
more strongly among current smokers than in
never-smokers. Calle et al. [5] revealed significant
positive linear trends in death rates with increas-
ing BMI for all cancers in men and women, with
the exclusion of participants with a BMI of less
than 18.5 from the analyses. Among those who had
never smoked the positive association was of
greater magnitude than in the total population.
The heaviest men (those with a BMI of at least 30)
had death rates from all cancers that were 52%
higher than the rates in men of normal weight. In
a Swedish cohort a comparable 33% excess inci-
dence of cancer was seen in obese persons [22]; no
results on lower BMI categories were presented.
The divergent findings on the association between
BMI and overall cancer risk may be attributable to
the wider or narrower range of BMI-values be-
tween studies, to the BMI categorization, to bias
introduced by reverse causality, i.e. by the effect of
occult cancer on body weight, to bias due to the
weight-lowering effect of smoking, and/or to the
percentage of smoking-related cancers of the total
group of cancer [5]. 
In our cohort study 87 of 290 cancer deaths
were due to lung cancer. No significant association
between BMI and lung cancer mortality was ob-
served. Thus, our results provide no evidence for
an elevated risk of lung cancer  in association with
lower levels of BMI. This was previously seen in
all but one of five cohort and three case-control
studies considered in a review of the International
Agency for Research on Cancer (IARC) [4]. Since
cigarette smoking is directly associated with lung
cancer risk and inversely associated with BMI, the
inverse association of BMI with lung cancer ob-
served in most studies may be the result of incom-
plete adjustment for the effects of smoking. Ac-
cordingly, Rauscher et al. [23] found in their case-
control study among former and never smokers
that persons in the upper octile of BMI had a
twofold greater risk of lung cancer. Obese persons
are known to have higher circulating levels of in-
sulin, which may act as a growth factor on cancer
cells directly by activating its own receptor or the
per unit increase of BMI (unit = 1 kg/m2) was 1.03
(95% CI: 0.99–1.07). In relation to lung cancer,
mortality neither increased nor decreased with in-
creasing BMI. The corresponding RR per 1-unit
increase of BMI was 1.0 (95% CI 0.93–1.07). The
results for prostate cancer mortality were similar,
i.e. no correlation with BMI was observed. The RR
corresponding to a 1-unit increase of BMI was 0.95
(95% CI: 0.93–1.18). The same was true for colon
cancer mortality. An increase of BMI by one unit
resulted in a RR of 1.09 (95% CI: 0.92–1.24). In
these calculations the potential confounding ef-
fects of smoking and age were taken into account
by allowing for multiple strata (see methods).
As there was no evidence for changes of risk
with BMI, we did not perform more detailed analy-
ses such as interactions of BMI with factors such
as “age at entry” or “smoking status”. 
Discussion
Site of cancer RR* per unit Lower 95% Upper 95% p-value
increase of BMI confidence limit confidence limit
All cancers 1.03 0.99 1.07 0.12
(n = 290)
Lung cancer 1.0 0.93 1.07 0.96
(n = 87)
Prostate cancer 0.95 0.93 1.18 0.42
(n = 30)
Colon cancer 1.09 0.92 1.24 0.2
(n = 22)
BMI, body mass index, which is calculated as weight in kilograms divided by the square of height in meters
* The risk is defined as exp(b), where b is the coefficient of BMI in the corresponding Cox regression model.
It means that the risk changes by a factor exp(b) when the BMI changes 1 unit (kg/m2). The analysis was
stratified according to the potential confounders “age” and “smoking”.
Table 3.
Relative risks (RR)
and 95% confidence
intervals (CI) for fatal
overall, lung,
prostate and colon
cancer by 1-unit in-
crease of body mass
index (BMI): follow-
up of 2974 male par-
ticipants of the Basel
study 1971/73–1990
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receptor for IGF-I, a potent mediator of cell
growth and survival [24]. 
Several cohort studies suggested that an in-
verse association berween BMI and lung cancer
risk was limited to those who developed lung can-
cer in the first years of follow-up [4]. Thus, the in-
verse association observed between BMI and lung
cancer may also be explained by weight loss due to
preclinical lung cancer. In the present study we did
not attempt to control the effect of pre-existing
cancer. No information on recent weight loss was
available and no screening for cancer had been
done at baseline. Furthermore, as Allison et al.
pointed out, to the extent that the exclusion of the
first few years of follow-up from the analyses has
any effect, the observation of this reduction may
be attributed to occult disease when in fact it could
be the lowering of the overall age of subjects rather
than the elimination of subjects with pre-existing
occult disease [13].
As for lung cancer, our study did not observe
a significant association between per unit increase
of BMI and prostate cancer mortality. Previous stud-
ies on the relationship between incident prostate
cancer and BMI have been inconsistent, finding no
association particularly in case-control studies, a
small increased risk (for references see [6, 25]) or
even an inverse association [26, 27]. In contrast, an
increased risk associated with obesity was sus-
pected for prostate cancer mortality [6, 22, 28, 29].
Accordingly, Andersson et al. [28] found in their
cohort study of prostate cancer incidence and mor-
tality a stronger association between BMI and
prostate cancer mortality (RR: 1.40) than was seen
with incidence (RR: 1.13). Three other studies
[30–32] assessed whether BMI predicted more ad-
vanced incidence prostate cancer, but the results
were not consistent. Accordingly, the IARC [4]
concluded that although the majority of the signif-
icant associations with body mass were found in
studies which focused on fatal or more aggressive
tumours, a clear pattern of a stronger association
for the more clinically significant forms of the
disease has not been consistently observed. BMI
reflects both lean body mass and adipose tissue,
and thus may not be an ideal measure for stud-
ies of an androgen-dependent tumour, such as
prostate cancer, since lean body mass is related to
androgen levels [4]. 
Although the relationship of BMI to colon
cancer has been studied extensively, there does not
appear to be a clear consensus [2, 3]. Obese men
have been reported to be at higher risk of colorectal
cancer, whereas data for women has been more in-
consistent [for references see 2, 3, 4]. Even though
our negative findings are in accordance with the
results of a few other studies [33, 34], they are
rather due to the small number of colon cancer
deaths (n = 22) in the present study.
Overall, the associations between BMI and
cancer mortality of various sites should be inter-
preted within the limitations of the present study.
Strengths of our study include the completeness of
follow-up of all study participants and the rather
homogenous socioeconomic status of the 2974
men. A limitation of our study was that we had to
rely on measured body weight at a single point in
time. Furthermore, there was no information on
(recent) weight loss and no screening for cancer
had been done at baseline. In addition, at baseline
no information was collected on past smoking, du-
ration, age at which smoking started, and depth of
inhalation.
In conclusion, our prospective data do not sup-
port an association between current body mass
index and mortality of all cancers combined, and
cancer of the lung prostate and colon. 
Acknowledgement: We are especially grateful to Dr.
James Young (Institute for Clinical Epidemiology, Uni-
versity hospital, Basel) for his statistical advice. We thank
Nina Maria Wieser (Word Force Translations, Zurich) for
her valuable comments.
Correspondence:
PD Dr. Monika Eichholzer
Institute for social and preventive medicine
Sumatrastrasse 30
CH-8006 Zürich
E-Mail: monika.eichholzer@balcab.ch
References
1 National Task Force on the Prevention and Treatment of Obe-
sity. Overweight, obesity, and health risk. Arch Intern Med
2000;160:898–904.
2 World Cancer Research Fund and American Institute for Can-
cer Research. Food, nutrition and the prevention of cancer: a
global perspective. Washington: AICR, WCRF; 1997.
3 Carroll KK. Obesity as a risk factor for certain types of cancer.
Lipids 1998:33:1055–9.
4 Vainio H, Bianchini F. Weight control and physical activity.
IARC handbooks of cancer prevention, vol 6. Lyon: IARC
Press, 2002.
5 Calle E, Rodriguez C, Walker-Thurmond K, Thun MJ. Over-
weight, obesity, and mortality from cancer in a prospectively
studied cohort of U.S. adults. N Engl J Med 2003;348:1625–38.
6 Rodriguez C, Patel A, Calle E, Jacobs E, Chao A, Thun M. Body
mass index, height, and prostate cancer mortality in two large
cohorts of adult men in the United States. Cancer Epidemiol
Biomarkers Prev 2001;10:345–53.
7 Henley SJ, Flanders WD, Manatunga A, Thun MJ. Leanness
and lung cancer risk: fact or artefact? Epidemiology 2002;13:
268–76. 
8 Capra S, Ferguson M, Ried K. Cancer: Impact of nutrition in-
tervention outcome – nutrition issues for patients. Nutrition
2001;17:769–72.
9 DeWys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino
JR, et al. Prognostic effect of weight loss prior to chemother-
apy in cancer patients. Am J Med 1980;69:491–7.
10 Corli O, Cozzolino A, Battaiotto L, Bernoni M, Gallina A. A
new method of food intake quantification: application to the
care of cancer patients. J Pain Symptom Manage 1992;7:12–7.
11 Manson JE, Stampfer MJ, Hennekens CH, Willett WC. Body
weight and longevity. JAMA 1987;257:353–8.
S W I S S  M E D  W K LY 2 0 0 5 ; 1 3 5 : 2 7 – 3 3  ·  w w w. s m w. c h 33
12 Allison DB, Heo M, Flanders DW, Faith MS, Williamson DF.
Examination of “early mortality exclusion” as an approach to
control for confounding by occult disease in epidemiologic
studies of mortality risk factors. Am J Epidemiol 1997;146:
672–80.
13 Allison DB, Faith MS, Heo M, Townsend-Butterworth D,
Williamson DF. Meta-analysis of the effect of excluding early
deaths on the estimated relationship between body mass index
and mortality. Obes Res 1999;7:342–54.
14 Cox DR. Regression models and life tables. J roy statist soc (ser.
B) 1972;34:187–220.
15 Kalbfleisch JD, Prentice RL. The statistical analysis of failure
time data. New York: John Wiley;1980.
16 Grambsch P, Therneau T. Proportional hazards tests and diag-
nostics based on weighted residuals. Biometrika 1994;81:
515–26.
17 S-Plus Version 6.1 for Windows: 2002. 
18 Seidell JC, Verschuren W, van Leer E, Kromhout D. Over-
weight, underweight, and mortality. A prospective study of
48287 men and women. Arch Intern Med 1996;156:958–63.
19 Baik I, Ascherio A, Rimm E, Giovannucci E, Spiegelman D,
Stampfer M, et al. Adiposity and mortality in men. Am J Epi-
demiol 2000;152:264–71.
20 Garfinkel L. Overweight and mortality. Cancer (Phila.) 1986;
58:1826–9.
21 Inoue M, Sobue T, Tsugane S, JPHC Study Group. Impact of
body mass index on the risk of total cancer incidence and mor-
tality among middle-aged Japanese: data from a large-scale pop-
ulation-based cohort study – The JPHC Study. Cancer Causes
Control 2004;15:671–80.
22 Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK,
Fraumeni JF, et al. A prospective study of obesity and cancer risk
(Sweden). Cancer Causes Control 2001;12:13–21.
23 Rauscher GH, Mayne ST, Janerich DT. Relation between body
mass index and lung cancer risk in men and women never and
former smokers. Am J Epidemiol 2000;152:506–13.
24 Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like
growth factor-I (IGF-I), IGF binding proteins, their biologic
interactions, and colorectal cancer. J Natl Cancer Inst 2002;
94:972–80.
25 Engeland A, Tretli S, Bjorge T. Height, body mass index, and
prostate cancer: a follow-up of 950000 Norwegian men. Br J
Cancer 2003;89:1237–42.
26 Porter MP, Stanford JL. Obesity and the risk of prostate can-
cer. Prostate 2004;9999:1–6
27 Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC.
Body mass index and risk of prostate cancer in U.S. Health Pro-
fessionals. J Natl Cancer Inst 2003;95:1240–1244.
28 Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G,
Englund A, et al. Body size and prostate cancer: a 20-year fol-
low-up study among 135006 Swedish dish construction work-
ers. J Natl Cancer Inst 1997;89:385–9.
29 Snowdown DA, Phillips RL, Choi W. Diet, obesity, and risk of
fatal prostate cancer. Am J Epidemiol 1984:120;244–50.
30 Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett
WC. Height, body weight, and risk of prostate cancer. Cancer
Epidemiol Biomarkers Prev 1997;6:557–63.
31 Cerhan JR, Torner JC, Lynch CF, Rubenstein LM, Lemke JH,
Cohen MB, et al. Association of smoking, body mass, and phys-
ical activity with risk of prostate cancer in the Iowa 65+ Rural
Health Study (United States). Cancer Causes Control 1997;
8:229–38.
32 Schuurman AG, Goldbohm RA, Dorant E, van den Brandt P.
Anthropometry in relation to prostate cancer risk in the Nether-
lands Cohort Study. Am J Epidemiol 2000;151:541–9.
33 Suadicani P, Hein HO, Gyntelberg F. Height, weight, and risk
of colorectal cancer. An 18-year follow-up in a cohort of 5249
men. Scand J Gastroenterol 1993;28:285–88.
34 Tamakoshi K, Wakai K, Kojima M, Watanabe Y, Hayakawa N,
Toyoshima H, et al. A prospective study of body size and colon
cancer mortality in Japan: The JACC Study. Int J Obes 2004;
28:551–8.
What Swiss Medical Weekly has to offer:
• SMW’s impact factor has been steadily 
rising, to the current 1.537
• Open access to the publication via
the Internet, therefore wide audience 
and impact
• Rapid listing in Medline
• LinkOut-button from PubMed 
with link to the full text 
website http://www.smw.ch (direct link
from each SMW record in PubMed)
• No-nonsense submission – you submit 
a single copy of your manuscript by 
e-mail attachment 
• Peer review based on a broad spectrum 
of international academic referees
• Assistance of our professional statistician
for every article with statistical analyses
• Fast peer review, by e-mail exchange with
the referees 
• Prompt decisions based on weekly confer-
ences of the Editorial Board
• Prompt notification on the status of your
manuscript by e-mail
• Professional English copy editing
• No page charges and attractive colour 
offprints at no extra cost
Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich 
(Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne
International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, 
The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy
We evaluate manuscripts of broad clinical
interest from all specialities, including experi-
mental medicine and clinical investigation.
We look forward to receiving your paper!
Guidelines for authors:
http://www.smw.ch/set_authors.html
All manuscripts should be sent in electronic form, to:
EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnsburgerstrasse 8
CH-4132 Muttenz
Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch
Swiss Medical Weekly: Call for papers
Swiss 
Medical Weekly
The many reasons why you should 
choose SMW to publish your research 
Official journal of
the Swiss Society of Infectious disease
the Swiss Society of Internal Medicine
the Swiss Respiratory Society
Impact factor Swiss Medical Weekly 
0 . 7 7 0
1 . 5 3 7
1 . 1 6 2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
2
2
0
0
3
2
0
0
4
Schweiz Med Wochenschr (1871–2000)
Swiss Med Wkly (continues Schweiz Med Wochenschr from 2001) 
Editores Medicorum Helveticorum
